Dlugos, D; Worrell, G; Davis, K; Stacey, W; Szaflarski, J; Kanner, A; Sunderam, S; ... Dingledine, R; + view all Dlugos, D; Worrell, G; Davis, K; Stacey, W; Szaflarski, J; Kanner, A; Sunderam, S; Rogawski, M; Jackson-Ayotunde, P; Loddenkemper, T; Diehl, B; Fureman, B; Dingledine, R; - view fewer (2016) 2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Currents , 16 (3) pp. 192-197. 10.5698/1535-7511-16.3.192.

Preview

Text 1535-7511-16%2E3%2E192.pdf - Published Version Download (287kB) | Preview

Abstract

The Epilepsy Benchmark goals in Area III focus on making progress in understanding and controlling seizures and related conditions as well as on developing biomarkers and new therapies that will reduce seizures and improve outcomes for individuals with epilepsy. Area III emphasizes a need to better understand the ways in which seizures start, propagate, and terminate and whether those network processes are common or unique in different forms of epilepsy. The application of that knowledge to improved seizure prediction and detection will also play a role in improving patient outcomes. Animal models of treatment-resistant epilepsy that are aligned with etiologies and clinical features of human epilepsies are especially encouraged as necessary tools to understand mechanisms and test potential therapies. Antiseizure therapies that target (either alone or in combination) novel or multiple seizure mechanisms are prioritized in this section of the Benchmarks. Area III goals also highlight validation of biomarkers of treatment response and safety risk, effective self-management, and patient-centered outcome measures as important areas of emphasis for the next five to ten years.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item